Active mutations in the EGFR-tyrosine kinase domain, such as exon 19 deletion and exon 21L858R, are found specifically in lung cancer and are not common in other cancers; for example, the frequency of EGFR mutations in colon cancer is 3% and lung-cancer-specific mutations are rare [37]. This evidence concerns the gene EGFR and lung carcinoma.